Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for GI GVHD Prevention in AHCT Patients
NCT03862079Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Fecal Microbiota Transplantation Capsule in graft-versus-host disease (GVHD) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Development of acute gastrointestinal graft versus host disease at 100 days and Relapse-free survival at 6 months. Planned start Jun 2020; status: withdrawn.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03862079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03862079.